An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2yDOrbd
via IFTTT